Document:

EX-4.1

 Exhibit 4.1 
  

 
 STRICTLY PRIVATE & CONFIDENTIAL 
  

			
			 URGENT

			 FAX OR EMAIL ACCEPTANCE REQUIRED BY

			 April 20, 2015 (New York, USA)

 Bid Ref:              

To the Investor named in the attached Combined Placement 

Acceptance & Confirmation of Registration Advice (“you”) 

PLACEMENT CONFIRMATION LETTER 

Proposed Placement of up to 51.75 million ordinary shares at AUD$0.30 per share to raise up to AUD$15.525 million, together with options
to purchase up to 51.75 million shares with an exercise price of AUD$0.30 per option and up to 25.875 million shares with an exercise price of AUD$0.40 per option to the undersigned or nominee 

 

	1.	Introduction 

 Novogen Limited, an Australian corporation with Australian Company Number 063 259 754
(“the Company”), is pleased to invite you take a placement of new ordinary shares in the Company (“the Shares”) at an issue price of AUD$0.30 per Share to raise up to an aggregate of AUD$15,525,000 before costs of the issue, (the
“Placement”) and for no additional cash consideration be granted: 
  

	•	 	One new option with an exercise price of AUD$0.30 per option and expiry date of six months following the earlier of (i) the date of effectiveness of the Registration Statement (defined below) or (ii) the date
on which the ordinary shares underlying the options are eligible for resale under Rule 144 (each, a “First Option”) for every one Share placed; and 

  

	•	 	One new option with an exercise price of AUD$0.40 per option and expiry date of the 5th anniversary of the date of issue of the options (each, a “Second
Option”) for every two Shares placed, 

 (the First Options and Second Options collectively called the “Options”). 

The Shares and Options (the “Placement Securities”) will be issued in two tranches. The Shares and such of the First Options as may be issued
without shareholder approval will be issued on payment by you (collectively, “the First Tranche”). The Second Options (and if there is insufficient headroom to issue all the First Options in the First Tranche, such unissued First Options)
(collectively, “the Second Tranche Options”) will be issued after, and subject to the approval of, the Options Resolutions referred to in paragraph 4(c) below. 
  

	2.	Offer 

 You are hereby offered to participate in the Placement, subject to the terms set out below in
this letter. Please complete and return Part One of the attached Combined Placement Acceptance & Confirmation of Registration Advice by April 20, 2015 (New York, USA), indicating the number of Placement Securities you agree to purchase
under this Placement. 

 Your payment in respect of the Placement Securities is to be made in clear funds to the account specified in
paragraph 15 of this letter and must be received by the Company by no later than 5:00 p.m. (New York, USA time), April 24, 2015 (the “Payment Date”). 

To facilitate settlement of your allotment of Placement Securities, please also complete and return Part Two (Registration Details) of the Combined Placement
Acceptance & Confirmation of Registration Advice to the Company at your earliest convenience and in any event by no later than April 23, 2015 (New York, USA). If nominating one or more associated entity(ies) to be the recipient of the
Placement Securities, please complete Part Two of the Combined Placement Acceptance & Confirmation of Registration Advice accordingly. 
 The
Placement Securities to be issued in the First Tranche shall be delivered to you, subject to the conditions set out in paragraph 4 below, by no later than 1 business day following the Payment Date. 

 

	3.	Use of Proceeds 

 The purpose of the Placement is to fund further and ongoing research programs and to
fund working capital requirements of the Company, after payment of the costs of the Placement. 
 H.C. Wainwright & Co., LLC (the “Placement
Agent”) is the exclusive placement agent in this transaction and receive compensation for such services from the proceeds of the Placement. 
  

	4.	Further Conditions of Placement, Option Allotment and Resets 

  

	(a)	For a period of 90 days following the date of this letter, the Company shall not undertake any other new issue(s) of ordinary shares or options to purchase ordinary shares to a third party(ies) other than an offer of
ordinary shares and options to existing shareholders and/or ADS holders of the Company (including an issue of shortfall shares and options) to raise up to AUD$15 million and to be announced on or about the date of announcement by the Company of the
Placement (“Approved Issue”). An issue of shares on the exercise of options existing at the date of this letter or issued pursuant to an Approved Issue shall not constitute a new issue. 

 

	(b)	From the date hereof until April 20, 2016, the Company shall be prohibited from effecting or entering into an agreement to effect any issuance by the Company or any of its subsidiaries of ordinary shares or
securities convertible, exercisable, or exchangeable for, ordinary shares, (including, without limitation, any American Depository Shares or American Depository Receipts) (or a combination of units thereof) involving a Variable Rate Transaction.
“Variable Rate Transaction” means a transaction in which the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include the right to receive, additional ordinary
shares either (A) at a conversion price, exercise price or exchange rate or other price that is based upon, and/or varies with, the trading prices of or quotations for the ordinary shares (or ADSs or ADRs) at any time after the initial issuance
of such debt or equity securities or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified or
contingent events directly or indirectly related to the business of the Company or the market for the ordinary shares (or ADSs or ADRs) or (ii) enters into any agreement, including, but not limited to, an equity line of credit, whereby the
Company may issue securities at a future determined price. The undersigned shall be entitled to obtain injunctive relief against the Company to preclude any such issuance, which remedy shall be in addition to any right to collect damages.

  
 - 2 - 

	(c)	Each Option will entitle its holder upon payment of the exercise price to one ordinary share in the capital of the Company. The Options will not be listed unless the Company at its discretion applies to ASX Limited ACN
008 624 691 (“ASX”) and the requirements of ASX for an additional class of securities are able to be satisfied. 

The placement of the Second Tranche Options is subject to the prior approval of the shareholders of the Company under ASX Listing Rule 7.1. The
Company will convene a general meeting (“the EGM”) within 60 days of the date of this letter at which resolutions will be put to the shareholders of the Company to consider the approval of the proposed placement of the Second Tranche
Options under ASX Listing Rule 7.1 (“the Options Resolutions”). 
 If any of the Options Resolutions is not passed at the EGM, the
Company will not issue securities in the Company other than Second Tranche Options and the Approved Issue until all the Second Tranche Options are placed as agreed. 

The Company will not be in breach of the agreement arising from your acceptance of the offer contained in this letter (“this
Agreement”) or any obligation in any way if any Option Resolution in the EGM is not passed. 
  

	(d)	Your payment in respect of the Placement Securities is to be made in clear funds to the account specified in paragraph 15 of this letter and must be received by the Company no later than 5:00 p.m. (New York, USA time)
on April 24, 2015. 

 If the Company does not receive full payment in accordance with this sub-paragraph (d) by
May 1, 2015, the Company may, at its discretion, terminate this Agreement by written notice to you, without prejudice to its other accrued rights and remedies; provided, however, that, in the event of the Company’s
termination of this Agreement with respect to any purchaser hereunder, the Company shall first offer the Placement Securities that are subject to such termination by the Company to the other purchasers to this Agreement on the date hereof on the
same terms and conditions, provided that, if more than one other purchaser wishes to purchase such Placement Securities, the Company shall offer the Placement Securities to such purchasers on a pro-rata basis on the basis of such purchasers’
respective purchase prices hereunder. 
  

	(e)	Upon the issue of the Shares, the Company shall take such steps as are required to procure expeditiously the satisfaction of the following: 

(i) Within 15 Business Days after the passing of the Options Resolutions, the Company agrees to file a registration statement
(“Registration Statement”) under the U.S. Securities Act of 1933, as amended (“Securities Act”) of American Depository Receipts (“ADRs”) covering the Shares and ordinary shares issuable upon exercise of the Options and
use commercially reasonable efforts to cause the Registration Statement to be declared effective as soon as reasonably possible (or, in the event of a “full review” by the Securities and Exchange Commission (“SEC”), 50 Business
Days after the filing of the Registration Statement). Such registration to be maintained for the greater of six months or such time as the ADRs covering the Shares are eligible for sale under Rule 144. In the event that the Registration Statement is
(A) not filed on or before 15 Business Days after the passing of the Options Resolutions, (B) not declared effective on or prior to 30 Business Days after the filing of the Registration Statement (or, in the event of a “full
review” by the SEC, 50 Business Days after the filing of the Registration Statement) or (C) the Registration Statement ceases for any reason to remain continuously effective as to the ADRs covering the Shares for the greater of six months
or such time as the ADRs covering the Shares are eligible for sale under Rule 144 (A, B and C collectively, an “Event”), then after the occurrence and pendency of an Event until the Event is cured, the Company shall pay to you an amount in
cash equal to 1.5% per month (applied ratably for partial months) of the amount paid for you hereunder for any Placement Shares then held by you; provided that such liquidated damages shall cease to accrue in the event that Rule 144 under the
Securities Act is available to you for the resale of the Placement Shares without volume or manner restrictions. 

  
 - 3 - 

 (ii) Following the registration of the ADRs under the Securities Act, Shares may be converted to
ADRs and the undersigned shall reimburse the Company for the reasonable costs of such conversion. 
  

	(f)	The Company agrees and covenants that, prior to the approval of the shareholders of the Company of the placement of the Options, any and all ordinary shares that are available for issuance by the Company shall be first
allocated and reserved by the Company for issuance of shares upon exercise of the Options. 

  

	5.	Rights Attaching to the Placement Securities 

 The Shares and the shares issuable upon exercise of the
Options (collectively, “the Placement Shares”) will rank pari passu in all respects with the existing shares of the Company from their respective dates of issue. 

The Company will apply to ASX for official quotation of the Shares and, subject to receiving shareholder approval to the Options Resolutions, the shares
issuable upon exercise of the Options on ASX and will use best efforts to maintain listing of the ADRs on the Nasdaq Capital Market (“NASDAQ”). 

Please note that ASX Market Participants (as defined in the ASX Market Rules) cannot deal in the Placement Shares either as principal or agent until official
quotation of the relevant Placement Shares is granted. 
  

	6.	Offer Personal 

 The offer of Placement Securities to you on the terms and conditions set out in this
letter and the agreement arising from your acceptance of the offer is personal to you and (other than by nominating an associated entity to be the recipient of the Placement Securities in Part Two of the Acknowledgement in Combined Placement
Acceptance & Confirmation of Registration Advice, in which case any reference to “you” or “your” in this letter includes that nominated associated entity) you may not prior to settlement of the Placement assign,
transfer, or in any other manner, deal with the Placement Securities, or your rights or obligations under this Agreement, without the prior written agreement of the Company. 
  

	7.	Acceptance Binding 

 You agree to be bound by this Agreement, as evidenced by your execution of Part One
of the Acknowledgement in Combined Placement Acceptance & Confirmation of Registration Advice, notwithstanding any changes to the anticipated timetable. 

  
 - 4 - 

	8.	Restricted Trading of Placement Securities in the United States 

 The Placement Securities and the
ordinary shares issuable upon exercise of the Options (collectively, the “Securities”), have not been registered under the Securities Act or the securities laws of any state. The issue to you of the Securities is being made in reliance on
the exemption from such registration provided by Section 4(a)(2) of the Securities Act and Rule 506 thereunder, and exemptions under applicable state laws. 

For purposes of Australian securities law, the Securities are not being offered by the Company with the purpose that you sell or transfer any of the
Securities or grant, issue or transfer any interests in or options over them. You agree that you are acquiring the Securities for your own account and not with a view to the resale, distribution or other disposition thereof in violation of the
registration requirements of U.S. federal or state securities laws. For avoidance of doubt, this paragraph does not require the purchaser to hold the securities for any specified length of time. 

The Securities are “restricted securities” under Rule 144(a) (3) under the Securities Act. If you decide to offer, sell, pledge or otherwise
transfer all or any part of the Securities, they may be offered, sold, pledged or otherwise transferred only: 
  

	(a)	to the Company; 

  

	(b)	outside the United States in accordance with Rule 904 of Regulation S under the Securities Act (“Regulation S”), including in regular brokered transactions on the ASX, and in compliance with applicable local
laws and regulations; 

  

	(c)	in accordance with Rule 144A under the Securities Act; 

  

	(d)	pursuant to a registration statement under the Securities Act; 

  

	(e)	pursuant to another exemption from registration under the Securities Act; and 

  

	(f)	in each case, in compliance with any applicable state securities laws of the United States, after, in the case of proposed transfers under sub-paragraph (e) immediately above, you have furnished to the Company an
opinion of counsel of recognized standing or other evidence reasonably satisfactory to the Company to the effect that the proposed transfer may be made without registration under the Securities Act and any applicable state securities laws.

  

	9.	Representations, Warranties, Undertakings and Agreements 

 By accepting this offer of Securities, you
represent, warrant, undertake and agree for the benefit of the Company, its affiliates and the Placement Agent that: 
  

	(a)	If you are in Australia, you are one of the following: 

  

	 	(i)	a “Sophisticated Investor” within the meaning of section 708(8) of the Corporations Act 2001 (Commonwealth) (“Corporations Act”); or 

 

	 	(ii)	a “Professional Investor” within the meaning of section 708(11) of the Corporations Act; or 

  
 - 5 - 

	 	(iii)	an entity which is otherwise exempt from the requirement for the Company to give you a disclosure document (prospectus) under Chapter 6D of the Corporations Act; 

 

	(b)	If you are in the United States, you are a person to whom an invitation or offer to subscribe for the Placement Securities in the manner contemplated by this Agreement is permitted by the laws of the jurisdiction in
which you are situated or from where you submitted a bid to subscribe for Placement Securities and you are a person to whom the Placement Securities can lawfully be issued under all applicable laws, without the need for any registration, lodgement,
filing or approval and you are an “accredited investor,” as defined in Regulation D under the Securities Act that has at least $5 million of assets and was not formed for the specific purpose of acquiring the Placement Securities.

  

	(c)	You are aware that publicly available information about securities in the Company can be obtained from the Australian Securities and Investments Commission and ASX (including the ASX’s website at: www.asx.com.au),
and that certain publicly available information about securities of the Company can be obtained free of charge from the Company’s website at: www.novogen.com. 

 

	(d)	You have had access to all information that you believe is necessary or appropriate in connection with your acquisition of the Placement Securities. You acknowledge and agree that you will not hold the Company or any of
its affiliates responsible for any misstatements in, or omissions from, any information concerning the Company or securities of the Company other than publicly available information published by the Company. 

 

	(e)	You have made and relied upon your own assessment of securities of the Company and have conducted your own investigations with respect to the Placement Securities including, without limitation, the particular tax
consequences of acquiring, owning or disposing of the Placement Securities in light of your particular situation as well as any consequences arising under the laws of any other taxing jurisdiction. 

 

	(f)	You have not relied on any investigation that the Company or affiliates or any persons acting on its behalf may have conducted with respect to the Placement Securities. None of such persons has made any representation
to you, express or implied, with respect to the Placement Securities. 

  

	(g)	You acknowledge that this Agreement does not constitute a securities recommendation and that the Company has not had regard to your particular objectives, financial situation and needs. 

 

	(h)	You acknowledge that an investment in the Placement Securities involves a degree of risk. 

  

	(i)	You have such knowledge and experience in financial and business matters that you are capable of evaluating the merits and risks of a purchase of the Placement Securities. 

 

	(j)	You have the financial ability to bear the economic risk of the investment in the Placement Securities. 

  

	(k)	You are not a related party (as defined in section 228 of the Corporations Act or treated by ASX as such for the purposes of ASX Listing Rule 10.11) of the Company. 

 

	(l)	You agree to accept any Placement Securities issued to you on the terms set out in this letter and subject to the constitution of the Company (“the Company Constitution”). 

  
 - 6 - 

	(m)	You will not deposit any Placement Securities into any unrestricted depositary receipt facility maintained by a depositary bank (i) until 40 days after the completion of the Placement if you are purchasing
Placement Securities outside the United States in compliance with Regulation S or (ii) if you are in the United States, until such time as such Placement Securities are no longer “restricted securities” within the meaning of Rule
144(a)(3) of the Securities Act. 

  

	(n)	You acknowledge that the Company and its affiliates are entitled to, and will, rely upon the truth and accuracy of the foregoing acknowledgments, representations, warranties and agreements. 

The Company represents, warrants and covenants as follows: 
  

	(1)	On or prior to the Payment Date, the Company shall have caused its Australian counsel to have delivered to you an Australian legal opinion in relation to the Placement in a form acceptable to the Placement Agent and its
US counsel to have delivered to you a US legal opinion in relation to the Placement in a form acceptable to the Placement Agent. 

  

	(2)	On or before 7:00 p.m. (New York City time) on April 20, 2015, the Company shall issue the press release in the form attached hereto in both the United States and Australia. The Company shall promptly thereafter
file the press release and this letter agreement in a Form 6-K with the Securities and Exchange Commission. After issuance of such press release, the Company warrants that you will not be in possession of any material non-public information
respecting the Company or the Company’s subsidiaries. Further, except with respect to the material terms and conditions of the transactions contemplated by this Agreement, which shall be disclosed pursuant to the press release described above,
the Company covenants and agrees that neither it, nor any other person acting on its behalf will provide the undersigned or its agents or counsel with any information that constitutes, or the Company reasonably believes constitutes, material
non-public information, unless prior thereto the undersigned shall have consented to the receipt of such information and agreed with the Company to keep such information confidential. The Company understands and confirms that the undersigned shall
be relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent that any notice required to be provided hereunder after the issuance of the press release pursuant to the second sentence of this section
constitutes, or contains, material, non-public information regarding the Company or any of its subsidiaries, the Company shall simultaneously file such notice with the SEC pursuant to a Form 6-K. In addition, effective upon the filing of the press
release, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its subsidiaries or any of their respective officers, directors,
affiliates, employees or agents, on the one hand, and you or any of your affiliates, on the other hand, shall terminate. To the extent that the Company, any of its subsidiaries or any of their respective officers, directors, affiliates employees or
agents delivers any material, non-public information to you or any of your affiliates without your consent, the Company hereby covenants and agrees that, to the extent permitted by law, you shall not have any duty of confidentiality to the Company,
any of its subsidiaries or any of their respective officers, directors, affiliates, employees or agents with respect to, or a duty to the Company, any of its subsidiaries or any of their respective officers, directors, affiliates, employees or
agents not to trade on the basis of, such material, non-public information. The Company understands and confirms that the undersigned shall be relying on the foregoing covenant in effecting transactions in securities of the Company.

  

	(3)	The Company will inform you immediately after the Registration Statement has been filed, after it has become effective, and if for any reason the Registration Statement has ceased to be effective. If the Registration
Statement ceases to be effective, the Company shall use best efforts to ensure that the Registration Statement again becomes effective as soon as possible. 

  
 - 7 - 

	(4)	The Placement Shares will be in a class of securities listed on the ASX. Upon issuing any of the Placement Shares, the Company will immediately make application to ASX for official quotation of those Placement Shares
and will lodge with ASX such other documents as are required for those Placement Shares to be freely tradeable on ASX without restriction (including issuing a cleansing notice in accordance with section 708A(5)(e) of the Corporations Act which
complies with the requirements of section 708A(6) of the Corporations Act (“Cleansing Notice”)) within 2 business days of being issued. If the Company is unable to issue a Cleansing Notice, it must instead issue and lodge a prospectus in
relation to Placement Shares in compliance with the requirements of section 708A(11) of the Corporations Act. 

  

	(5)	Subject to paragraph 8 above, it is understood and acknowledged by the Company that you have not been asked to agree to desist from purchasing or selling, long and/or short, securities of the Company, or
“derivative” securities based on securities issued by the Company or to hold the Shares or Options for any specified term. The Company further understands and acknowledges that you may engage in hedging and/or trading activities at various
times during the period that the Shares or Options are outstanding , to the extent such trading and hedging activities are in compliance with all applicable securities, and such hedging and/or trading activities, if any, can reduce the value of the
existing securityholders’ equity interests in the Company both at and after the time the hedging and/or trading activities are being conducted. The Company acknowledges that such aforementioned hedging and/or trading activities, assuming such
trading and hedging activities are in compliance with all applicable securities laws, do not constitute a breach of this Agreement or any of the documents executed in connection herewith. 

 

					
	(6)		(a)		The Company has filed with, or furnished to, the SEC, on a timely basis, all forms, reports, schedules, statements and other documents required to be filed by it since January 1, 2013 (collectively, the “Company SEC
Documents”). The Company has never been an issuer subject to Rule 144(i) under the Securities Act. The Company SEC Documents, as of their respective dates (or if amended prior to the date of this Agreement, as of the date of such
amendment):

  

	 	(i)	do not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they
were made, not misleading; and 

  

	 	(ii)	comply in all material respects with the applicable requirements of the Securities Exchange Act of 1934 (“Exchange Act”) and the Securities Act, as the case may be, and the applicable rules and regulations of
the SEC thereunder. 

  

	 	(b)	As of their respective dates (or if amended prior to the date of this Agreement, as of the date of such amendment), the financial statements of the Company included in the Company SEC Documents, including any related
notes thereto: 

  

	 	(i)	comply in all material respects with applicable accounting requirements and with the published rules and regulations of the SEC with respect thereto; 

 

	 	(ii)	have been prepared in accordance with International Financial Reporting Standards applied on a consistent basis during the periods involved (except as may be set forth in the notes thereto and subject, in the case of
the unaudited statements, to normal, recurring audit adjustments not material in amount); and 

  
 - 8 - 

	 	(iii)	fairly present in all material respects the consolidated financial position of the Company and its subsidiaries as at the dates thereof and the consolidated results of their operations and cash flows for the periods
indicated. 

  

	(7)	Organization; Qualification. The Company is a corporation duly organized, validly existing and, in jurisdictions where such concept is recognized, in good standing under the laws of the jurisdiction of its organization
and has all requisite corporate or limited liability company power and authority to own, license, use, lease and operate its assets and properties and to carry on its business as it is now being conducted and as currently proposed by management to
be conducted. 

  

	(8)	Authority. The Company has all requisite corporate power and authority to execute and deliver this Agreement and to perform and consummate this Agreement. This Agreement has been duly executed and delivered by the
Company and constitutes a valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general
applicability relating to or affecting creditors’ rights and to general principles of equity. 

  

	(9)	Consents and Approvals. 

  

	 	(a)	The execution, delivery and performance by the Company of this Agreement and the consummation by the Company of the actions contemplated herein do not and will not require any filing or registration with, notification
to, or authorization, permit, consent or approval of, or other action by or in respect of, any foreign, domestic, state or local governmental body, self-regulatory organization, court, agency, commission, official or regulatory or other authority
other than 

  

	 	(i)	the regulatory filings referred to herein; and 

  

	 	(ii)	compliance with the rules and regulations of the ASX and NASDAQ. 

  

	 	(b)	The execution, delivery and performance by the Company of this Agreement will not 

  

	 	(i)	conflict with or result in any breach of any provision of the Company’s Constitution; or 

  

	 	(ii)	result in a violation or breach of, or constitute (with or without due notice or lapse of time or both) a default under, or give rise to any right of termination, amendment, cancellation or acceleration or the creation
or acceleration of any right or obligation under, or result in the creation of any encumbrance upon, any of the properties or assets of the Company under any of the terms, conditions or provisions of any note, bond, mortgage, indenture, loan, credit
agreement, lease, license, permit, concession, contract, agreement or other instrument, understanding or obligation, whether written or oral, to which the Company is a party or by which any of its properties or assets may be bound; or

  

	 	(iii)	violate any judgment, order, writ, preliminary or permanent injunction or decree or any Australian law applicable to the Company, or any of its properties or assets, except in the case of clauses (ii) and
(iii) for violations, breaches, defaults, terminations, amendments, cancellations or accelerations that would not have a material adverse effect on the Company. 

  
 - 9 - 

	(10)	Absence of Certain Changes or Events. Since its most recent annual report to the date of this Agreement, the business of the Company has been conducted in all material respects in the ordinary course, consistent with
past practice and there has been no material adverse change in the financial condition, business, or operations of the Company, except as disclosed in the Company’s filings with the SEC. Without limiting the foregoing, since its most recent
annual report to the date of this Agreement, there has not occurred any damage, destruction or loss (whether or not covered by insurance) of any material asset of the Company or any of its subsidiaries which materially affects the use thereof, and
the Company has not defaulted on any material agreement to which it is bound. 

  

	(11)	Litigation. Except as disclosed in the Company’s public filings, as of the date of this Agreement, there is no suit, claim, action, proceeding or investigation pending before any court, regulatory agency or
authority, or governmental agency (each, a “Governmental Authority”) or arbitrator or that is, to the knowledge of the Company, threatened by or against the Company that seeks to enjoin any activities of the Company. The Company is not
subject to 

  

	 	(a)	any outstanding order, writ, judgment, decree or injunction of, or settlement with, any Governmental Authority; or 

  

	 	(b)	engaged in any suit, claim, action or proceeding to recover monies due to it or for damages or losses sustained by it that, if the Company failed to collect such monies due it, would have a material adverse effect on
it. 

  

	(12)	Compliance with Applicable Law. As at the date of this Agreement, the Company holds all permits, licenses, authorizations, certificates, variances, exemptions, orders and approvals of all governmental authorities
necessary for the lawful conduct of its business as presently conducted and to its assets and properties except for failures to hold any such permits that would not have a material adverse effect on the Company. 

 

	(13)	Taxes. Except as disclosed in its publicly filed documents, as at the date of this Agreement, the Company has filed, or has caused to be filed on its behalf, all material Australian and other foreign returns, estimates,
declarations, information statements and reports relating to taxes (“Returns”) required to be filed by the Company with any Tax authority, and such Returns are true and correct in all material respects. The Company and each of its
subsidiaries have paid all material taxes shown on such Returns that are due. 

  

	(14)	Insurance. As at the date of this Agreement, the Company maintains all policies of insurance that are required by applicable law and contracts relating to the Company. The insurance policies, to the knowledge of the
Company: 

  

	 	(a)	have been issued by insurers which are reputable and financially sound; 

  

	 	(b)	provide coverage for the operations conducted by the Company of a scope and coverage which the directors of the Company believe to be adequate; and 

 

	 	(c)	are in full force and effect. 

  
 - 10 - 

	(15)	Intellectual Property. 

  

	 	(a)	To the Company’s knowledge, as at the date of this Agreement, none of the intellectual property rights owned by the Company and disclosed in the Company’s most recent Annual Report on Form 20-F, the use by the
Company of any of such intellectual property rights, or the conduct of the business of the Company infringes, constitutes the misappropriation of or violates any valid intellectual property rights of any other person or, to the extent that any such
claims of infringement, misappropriation or violation are made or asserted against the Company, the Company has valid and reasonable counterclaims thereto of infringement of a material patent(s) that the Company has the valid right to assert or
enforce. 

  

	 	(b)	Except as disclosed in the Company’s most recent Annual Report on Form 20-F, the Company is the sole and exclusive owner of, or has valid and continuing rights (pursuant to written intellectual property licenses)
to use and otherwise exploit, the Company’s intellectual property rights as at the date of this Agreement. 

  

	(16)	Disclosure. As at the date of this Agreement and the Payment Date, There has been no failure by the Company to comply with its periodic and continuous disclosure obligations under the ASX Listing Rules and the
Corporations Act. 

  

	10.	Governing Law and Jurisdiction 

 This Agreement between the Company and you arising out of your
acceptance of the terms of this offer shall be governed by the laws of New York, USA. Both parties agree that all disputes arising hereunder shall be submitted to courts sitting in the County of New York, New York, USA. 

 

	11.	Entire Agreement 

 Subject to this paragraph, upon acceptance of the offer by you the terms contained in
this letter including, without limitation the Combined Placement Acceptance & Confirmation of Registration Advice, constitute the entire agreement between the Company and you as to the Placement to the exclusion of all prior
representations, understandings and agreements between the Company and you. Any variation of the terms of this Agreement must be in writing signed by the Company and you. However, the foregoing does not affect the enforceability of your commitment
not to withdraw or amend your acceptance of the offer of Placement Securities and to be bound to subscribe for Placement Securities allocated to you (“Allocated Placement Securities”). 

 

	12.	Notices 

 Any notice to be given relating to the offer of Placement Securities or your acceptance of the
Placement may be sent by facsimile or .pdf data file to the facsimile number or e-mail of the party to whom the notice is sent (as notified to the other party in writing) and will be deemed to have been given upon the successful transmission to that
facsimile number or e-mail address. 
  

	13.	Placement Acceptance Advice 

 In order to confirm you participation in the Placement, you agree to
execute and deliver a fully completed Combined Placement Acceptance & Confirmation of Registration Advice (in the form attached) which incorporates by reference the representations, warranties, undertakings and agreements set out in this
Placement Confirmation Letter. You must execute the Acknowledgement in such Combined Placement Acceptance & Confirmation of Registration Advice in respect of your Allocated Placement Securities and complete the details requested in it
(including in relation to stock lending transactions). The executed Acknowledgement in your Combined Placement Acceptance & Confirmation of Registration Advice is taken to be an application to subscribe (if relevant on behalf of your
settlement nominee) for the Allocated Placement Securities. 

  
 - 11 - 

 To confirm your irrevocable acceptance of the terms of the Placement, please sign and return a copy of the
Combined Placement Acceptance & Confirmation of Registration Advice to the Company to be received by the facsimile number or at the e-mail address shown in the form. 

 

	14.	Confirmation of Registration Advice 

 In order to facilitate the registration of the Allocated Placement
Securities, and as a condition of the issue of the Allocated Placement Securities, you agree to complete and return the Part Two of the Combined Placement Acceptance & Confirmation of Registration Advice. 

 

	15.	Settlement 

 You will be required to make full payment for your allocation of the Placement Securities by
5:00 p.m. (New York, USA time) on or about April 24, 2015 to: 
  

			
	Bank		Westpac
		
	SWIFT		WPACAU2S
		
	Account Number:		576674
		
	Account Name:		Novogen Ltd
		
	BSB:		032-285
		
	Reference:		[#]

 Any questions relating to settlement should be directed to [Graham Kelly] by telephone on +61 2 [9476 0344] or by fax on +61 2
[9476 0388]. 
  

			
	Yours faithfully,
	Novogen Limited
		
	By:		

		 	  

	Dr. Graham Kelly
	Chairman and Chief Executive Officer

  
 - 12 - 

 COMBINED 

PLACEMENT ACCEPTANCE & CONFIRMATION OF REGISTRATION ADVICE 

This form must be completed, signed and dated, and should be returned as soon as possible, either by facsimile (Fax No: +61 2 9476 0388) or to a
placement agent to the Placement: 
  

			
	To:	 	Novogen Limited
		 	16-20 Edgeworth David Avenue
		 	Hornsby, NSW 2077, Australia
		
	Attn:	 	Graham Kelly

 Dear Sirs, 
 PART ONE

  

	1.	Placement of up to 51.75 million ordinary shares at AUD$0.30 per share to raise up to AUD$15.525 million, together with options to purchase up to 51.75 million shares with an exercise price of AUD$0.30 per
option and up to 25.875 million shares with an exercise price of AUD$0.40 per option. 

 We refer to the Placement Confirmation
Letter from Novogen Limited (“the Company”) dated April 20, 2015 (“the Placement Letter”) regarding the placement by the Company of up to 51.75 million ordinary shares and options to purchase up to 51.75 million
shares with an exercise price of AUD $0.30 per option and up to 25.875 million shares with an exercise price of AuD$0.40 per option pursuant to the exercise of those options. We are pleased to confirm our irrevocable agreement to subscribe for
the following on the terms and conditions set out in the Placement Letter: 
  

							
	Placement Securities	  	No.	  	Total Amount	 
	 Ordinary shares

(at AUD$0.      per share)
	  		  	AUD$	            	  
			
	 1 Option (to acquire one share) for every 1 ordinary share placed, each having an exercise price of AUD$0.30 per option and an expiry
date of 6 months following the earlier of (i) the date of effectiveness of the Registration Statement or (ii) the date on which the ordinary shares underlying the options are eligible for resale under Rule 144,
	  		  	 	Nil (attaching)	  
			
	 1 Option (to acquire one share) for every 2 ordinary shares placed, each having an exercise price of AUD$0.40 per option and an expiry
date of five (5) years from the date of issue
	  		  	 	Nil (attaching)	  

  

	2.	Acknowledgement 

 The undersigned hereby confirms (for the benefit of the Company, its directors,
officers, employees, advisors and affiliates) the various representations, warranties and agreements contained in the Placement Letter, including those set forth in paragraph 9 of the Placement Letter. 

 

			
	Investor Details	  	
		
	Investor:	  	  

	(full name and ABN)	  	(Print)
		
	Settlement Contact Name:	  	  

		  	(Print)

  

									
	Telephone:	 	  
	 		 	Facsimile:	 	  

		 	(include country and area codes)	 		 		 	

  

									
	Authorised Signatory	 		 		 	
					
	Signature:	 	  
	 		 	Date:	 	  

					
	Name:	 	  
	 		 	Title:	 	  

 PLACEMENT ACCEPTANCE & CONFIRMATION OF REGISTRATION ADVICE 

(page two) 
  

 PART TWO 
  

	 	1.	Registration Details 

 Subject to terms and conditions of the Placement Confirmation Letter, the
Investor named in Part One of this Placement Acceptance Advice directs the Company to register the Allocated Placement Securities as follows: 

(Please complete the following information for settlement using more copies of this form for separate fund & payments). 

 

							
	Australian agent details						
				
	Agent Name:						  

				
	Agent Bic Code:						  

				
	Agent Chess account:						  

				
	Account name of beneficiary:						  

				
	Account Number of Beneficiary:						  

				
	Bic code of Beneficiary:						  

				
	Client contact for Payments				Phone		  

							(include country & area codes)
					Fax		  

				
	Client contact for Shares Settlement				Phone		  

							(include country & area codes)
					Fax		  

Settlement Contact Details (please provide details of your settlement person’s name and contact numbers): 

 

			
	Contact Name:		  

			(Print)

  

			
	Email:		  

			(Print)

  

									
	Telephone:		  
				Facsimile:		  

			(include country & area codes)						

 All settlement enquiries are to be directed to [Graham Kelly] at email ]Graham.Kelly@novogen.com] or telephone +61 2 [9476
0344]. 

  
 .../2 

 PLACEMENT ACCEPTANCE & CONFIRMATION OF REGISTRATION ADVICE 

(page three) 
  

	 	2.	Declaration 

 We confirm our agreement to accept the allocation of Shares and Options set out above,
confirm the allocation and registration details and understand our settlement obligations. 
  

			
	Signature:		  

		
	Name:		  

			(Print)

  

									
	Title:		  
				Date:		  

 Form          of         

  

 PRESS RELEASEEX-4.2

 Exhibit 4.2 

COMBINED 
 PLACEMENT
ACCEPTANCE & CONFIRMATION OF REGISTRATION ADVICE 
 This form must be completed, signed and dated, and should be returned as soon as
possible, either by facsimile (Fax No: +61 2 9476 0388) or to a placement agent to the Placement: 
  

			
	To:	 	Novogen Limited
		 	16-20 Edgeworth David Avenue
		 	Hornsby, NSW 2077, Australia
		
	Attn:	 	Graham Kelly

 Dear Sirs, 
 PART ONE

  

	1.	Placement of up to      million shares in Novogen Limited at AUD$0.30 each together with options to purchase up to      million shares (“the Placement Securities”).

 We refer to the Placement Confirmation Letter from Novogen Limited (“the Company”) dated April 20, 2015 (“the
Placement Letter”) regarding the placement by the Company of up to      million ordinary shares and options to purchase up to      million shares pursuant to the exercise of those options. We are
pleased to confirm our irrevocable agreement to subscribe for the following on the terms and conditions set out in the Placement Letter: 
  

									
	Placement Securities	  	No.	 	  	Total Amount	 
	 Ordinary shares

(at AUD$0.30 per share)
	  	 	11,000,000	  	  	AUD$	 3,300,000	  
			
	 1 Option (to acquire one share) for every 1 ordinary share placed, each having an exercise price of AUD$0.30 per option and an expiry
date of 6 months following the earlier of (i) the date of effectiveness of the Registration Statement or (ii) the date of approval on which the ordinary shares underlying the options are eligible for resale under Rule 144,
	  	 	11,000,000	  	  	 	Nil (attaching)	  
			
	 1 Option (to acquire one share) for every 2 ordinary shares placed, each having an exercise price of AUD$0.40 per option and an expiry
date of five (5) years from the date of issue
	  	 	5,500,000	  	  	 	Nil (attaching)	  

  

	2.	Acknowledgement 

 The undersigned hereby confirms (for the benefit of the Company, its directors,
officers, employees, advisors and affiliates) the various representations, warranties and agreements contained in the Placement Letter, including those set forth in paragraph 9 of the Placement Letter. 

 

			
	Investor Details	  	
		
	Investor:	  	 Anson Investments Master Fund LP

	(full name and ABN)	  	(Print)
		
	Settlement Contact Name:	  	 Anton Strgacic

		  	(Print)

  

									
	Telephone:	 	 416-447-8874
	 		 	Facsimile:	 	 416-352-1880

		 	(include country and area codes)	 		 		 	

  

									
	Authorised Signatory	 		 		 	
					
	Signature:	 	  
	 		 	Date:	 	 April 20 / 2015

					
	Name:	 	 Moez Kassam
	 		 	Title:	 	 Director, M5V Advisors Inc

 PLACEMENT ACCEPTANCE & CONFIRMATION OF REGISTRATION ADVICE 

(page two) 
  

 PART TWO 
  

	 	1.	Registration Details 

 Subject to terms and conditions of the Placement Confirmation Letter, the
Investor named in Part One of this Placement Acceptance Advice directs the Company to register the Allocated Placement Securities as follows: 

(Please complete the following information for settlement using more copies of this form for separate fund & payments). 

 

							
	Australian agent details						
				
	Agent Name:						 Citigroup Pty Limited

				
	Agent Bic Code:						 CITI AU 3X

				
	Agent Chess account:						 CHESS 20018

				
	Account name of beneficiary:						 NFS LLC EBOC

				
	Account Number of Beneficiary:						 2099100098

				
	Bic code of Beneficiary:						  

				
	Client contact for Payments				Phone		  

							(include country & area codes)
				
					Fax		  

				
	Client contact for Shares Settlement				Phone		  

							(include country & area codes)
				
					Fax		  

 Settlement Contact Details (please provide details of your settlement person’s name and contact numbers): 

 

			
	Contact Name:		 Roch Bialski

			(Print)

  

			
	Email:		 Roch.Bialski@FMR.com

			(Print)

  

									
	Telephone:		 617-392-1703
				Facsimile:		 877-236-8107

			(include country & area codes)						

 All settlement enquiries are to be directed to [Graham Kelly] at email [Graham.Kelly@novogen.com] or telephone +61 2 [9476
0344]. 

  
 .../2 

 PLACEMENT ACCEPTANCE & CONFIRMATION OF REGISTRATION ADVICE 

(page three) 
  

	 	2.	Declaration 

 We confirm our agreement to accept the allocation of Shares and Options set out above,
confirm the allocation and registration details and understand our settlement obligations. 
  

			
	Signature:	 	

		
	Name:	 	Moez Kassam
		 	(Print)

  

									
	Title:	 	 Director, M5V Advisors Inc
	 		 	Date:	 	 April 20 / 2015

 Form          of

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00247-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00247-of-00352.parquet"}]]